Use of clinical markers to identify metabolic syndrome in antipsychotic-treated patients

Journal of Clinical Psychiatry

Volumn 71, Issue 10, 2010, Pages 1273-1278

  Jin, Hua ^a,b   Meyer, Jonathan ^a,b   Mudaliar, Sunder ^b,c   Henry, Robert ^b,c   Khandrika, Srikrishna ^a   Glorioso, Danielle K ^a,b   Kraemer, Helena ^d   Jeste, Dilip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GHRELIN; HIGH DENSITY LIPOPROTEIN; INSULIN; LEPTIN; NEUROLEPTIC AGENT; PEPTIDE YY; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL TRIAL; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCREENING; SENSITIVITY AND SPECIFICITY; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BODY MASS INDEX; FEMALE; GHRELIN; HUMANS; INSULIN; LEPTIN; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PEPTIDE YY; ROC CURVE; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 78149291423     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05414yel     Document Type: Article

References (29)

1. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009;119(1):4-14. doi:10.1/j.160-047.208.01317.x PubMed
2. Obunai K, Jani S, Dangas GD. Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am. 2007;91(6):1169-1184, x. doi:10.1016/j.mcna.207.06.03 PubMed
3. Grundy SM, Cleeman JI, Merz CN, et al; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239. doi:10.161/01.CIR.01317.49796.0E PubMed
4. Assmann G, Guerra R, Fox G, et al. Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. Am J Cardiol. 2007;99(4):541-548. doi:10.1016/j.amjcard.206.08.045 PubMed
5. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med. 2005;118(suppl 2):15S-22S. PubMed
6. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32. doi:10.1016/j.schres.205.07.014 PubMed
7. Jakovljević M, Crncević Z, Ljubicić D, et al. Mental disorders and metabolic syndrome: a fatamorgana or warning reality? Psychiatr Danub. 2007;19(1-2):76-86. PubMed
8. Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7(5):424-430. doi:10.1/j.139-5618.205.0234.x PubMed
9. Cardenas J, Frye MA, Marusak SL, et al. Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 2008;106(1-2):91-97. doi:10.1016/j.jad.207.05.030 PubMed
10. Heiskanen TH, Niskanen LK, Hintikka JJ, et al. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry. 2006;67(9): 1422-1427. doi:10.408/JCP.v67n0913 PubMed
11. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res. 2000; 45(1-2):21-28. doi:10.1016/S0920-964(9)0191-7 PubMed
12. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59(4):337-345. doi:10.101/archpsyc.59.4.37 PubMed
13. Bushe C, Holt R. Prevalence of diabetes and impaired glucose intolerance in patients with schizophrenia. Br J Psychiatry suppl. 2004;184(47): s67-s71. doi:10.192/bjp.184.47.s67
14. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334-1349. doi:10.176/api.ajp.161.8.134 PubMed
15. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63(10):856-865. PubMed
16. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res. 2004;71(2-3):195-212. doi:10.1016/j.schres.204.03.024 PubMed
17. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-272. doi:10.408/JCP.v65n0219 PubMed
18. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. doi:10.1056/NEJMoa05168 PubMed
19. Buckley PF, Miller DD, Singer BE, et al. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res. 2005;79(2-3):281-288. doi:10.1016/j.schres.205.04.010 PubMed
20. Haupt DW, Rosenblatt LC, Kim E, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry. 2009;166(3):345-353. doi:10.176/api.ajp.208.08030383 PubMed
21. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-1495. doi:10.237/diacare.27.6.1487 PubMed
22. Woodward M. Epidemiological Study Design and Data Analysis. Boca Raton, FL: Chapman & Hall/CRC Press; 1999.
23. Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(22):2644-2650. doi:10.101/archinte.165.2.264 PubMed
24. Lorenzo C, Williams K, Hunt KJ, et al. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30(1):8-13. doi:10.237/dc06-1414 PubMed
25. Wahrenberg H, Hertel K, Leijonhufvud BM, et al. Use of waist circumference to predict insulin resistance: retrospective study. BMJ. 2005; 330(7504):1363-1364. doi:10.136/bmj.38429.47310.AE PubMed
26. Hirschler V, Maccallini G, Calcagno M, et al. Waist circumference identifies primary school children with metabolic syndrome abnormalities. Diabetes Technol Ther. 2007;9(2):149-157. doi:10.1089/dia.206.017 PubMed
27. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802-809. PubMed
28. Jin H, Meyer JM, Mudaliar S, et al. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res. 2008; 100(1-3):70-85. doi:10.1016/j.schres.207.1.026 PubMed
29. Bai YM, Chen JY, Yang WS, et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry. 2007;68(12):1834-1839. doi:10.408/JCP.v68n1202 PubMed